CORDIS
Wyniki badań wspieranych przez UE

CORDIS

Polski PL

Exgenome Molecular Enzymes

Cel

"The main objective of the EXGENOMES project is to develop new and improved thermostable enzymes for use, as reagents, in large-scale DNA synthesis and/or that can act on unnatural components such as in LNA (Locked Nucleic Acids). The target source for the new enzymes is a range of self-replicating mobile genetic elements (phages, plasmids and transposons) from thermophilic bacteria. Increased understanding of self-replication in many mobile genetic elements, such as phi29, has now made the commercial development of new self-priming & strand-displacing polymerases and other enzymes, much more plausible. A number of candidate enzymes, such as a new transposon-coded Thermus DNA polymerase are at hand for this project in the thermophilic bacteria & phage genome bank at Matis.

Nucleic acids based technologies now underpin a large and fast-growing industry, including research, diagnostics and pharmaceutical production. Thermophilic enzymes have played a key role in this development, as polymerases (DNA and RNA), ligases, nucleases, reverse transcriptases, polynucleotide kinases, lysozymes and more, are of great importance in the research industry today. The partner SME´s are all active players in this area from bioprospecting (Prokazyme), laboratory distribution (A&A Biotechnologies), LNA manufacture & diagnostics (Exiqon) to DNA vaccine production (Touchlight Genetics).

Together with the highly competent RTD partners the consortium is well positioned to implement the project according to its goals. The successful development of new thermostable polymerases and other enzymes with the desired properties would have a substantial impact on strengthening the current market status of the SME partners, resulting in growth in income and employment."
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Koordynator

PROKAZYME EHF

Adres

Vinlandsleio 14
113 Reykjavik

Islandia

Rodzaj działalności

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Wkład UE

€ 332 749

Kontakt administracyjny

Jakob Kristjansson (Dr.)

Uczestnicy (7)

Sortuj alfabetycznie

Sortuj według wkładu UE

Rozwiń wszystko

A&A BIOTECHNOLOGY SC

Polska

Wkład UE

€ 285 840

TOUCHLIGHT GENETICS LIMITED

Zjednoczone Królestwo

Wkład UE

€ 154 177

EXIQON AS

Dania

Wkład UE

€ 143 834

MATIS OHF

Islandia

UNIWERSYTET GDANSKI

Polska

INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY

Polska

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Zjednoczone Królestwo

Informacje na temat projektu

Identyfikator umowy o grant: 286556

Status

Projekt zamknięty

  • Data rozpoczęcia

    1 Grudnia 2011

  • Data zakończenia

    30 Listopada 2013

Finansowanie w ramach:

FP7-SME

  • Całkowity budżet:

    € 1 247 115

  • Wkład UE

    € 916 600

Koordynowany przez:

PROKAZYME EHF

Islandia